|
|
|
| Relationship between Serum HEPCIDIN Expression and Prognosis in Patients with COPD Complicated with Respiratory Failure |
| ZHOU Xiaomin, WANG Chengcun, ZHAO Zhanqing, et al |
| Western Central Hospital of Hainan, Hainan Danzhou 571799, China |
|
|
|
|
Abstract Objective: To investigate the relationship between serum HEPCIDIN expression and prognosis in patients with COPD complicated with respiratory failure. Methods: 115 cases of COPD complicated with respiratory failure (case group) and 52 cases of health examinees (control group) in our hospital were selected. The levels of CRP, WBC, HEPCIDIN, FEV1%, FEV1/FVC, and DLCO% were measured; moreover, the HEPCIDIN levels of patients with different degrees of hypoxemia were also measured. Results: The case group had higher levels of CRP, WBC, HEPCIDIN and IL-6 than those of the control group (P<0.05). HbA1c,FEV1%, FEV1/FVC and DLCO% in the case group were lower than the control group (P<0.05). The HEPCIDIN level was positively correlated with the degrees of hypoxemia (P<0.01). HEPCIDIN was negatively correlated with HbA1c, FEV1%, FEV1/FVC, and DLCO%, and positively correlated with CRP, WBC and IL-6 (P<0.05). High levels of HEPCIDIN, IL-6 and low levels of HbA1c, FEV1/FVC were risk factors for death of COPD with respiratory failure (P<0.05). The AUC, sensitivity and specificity of HEPCIDIN and HbA1c were similar (χ2=1.219, 1.695, P>0.05), which were lower than those of the FEV1/FVC (χ2=16.249, 17.023, P<0.05). Conclusion: Elevated serum HEPCIDIN levels are closely related to the severity of COPD disease; furthermore, high levels of HEPCIDIN, IL-6 and low levels of HbA1c ,FEV1/FVC are risk factors for the death of COPD and respiratory failure; As a predictor, the sensitivity and specificity of HEPCIDIN in diagnosis of COPD with respiratory failure are high and is worthy of clinical application.
|
|
|
|
|
|
[1] Toledopons N, Cosío BG, Velasco MD, et al. Chronic obstructive pulmonary disease in non-smokers[J]. Arch Bronconeumol, 2017, 53(2):45~46.
[2] Chan KY, Li X, Chen W, et al. Prevalence of chronic obstructive pulmonary disease (COPD) in China in 1990 and 2010[J].Glob Health, 2017, 7(2):020704.
[3] 张玲慧,孙洁,高晓粉,等.慢性阻塞性肺疾病急性加重期血清炎性标志物的研究进展[J].临床误诊误治,2018,31(5):109~111.
[4] Testa G, Cacciatore F, Bianco A, et al. Chronic obstructive pulmonary disease and long-term mortality in elderly subjects with chronic heart failure[J]. Aging Clinical and Experimental Research, 2017, 29(6):1157~1164.
[5] Wain LV, Shrine N, Artigas MS, et al. Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets[J]. Nature Genetics, 2017, 49(3):416~425.
[6] You LH, Yan CZ, Zheng BJ, et al. Astrocyte hepcidin is a key factor in LPS-induced neuronal apoptosis[J]. Cell Death and Disease, 2017, 8(3):e2676.
[7] Sangkhae V, Nemeth E. Regulation of the iron homeostatic hormone hepcidin[J]. Advances in Nutrition, 2017, 8(1):126~136.
[8] Michels KR, Zhang Z, Bettina AM, et al. Hepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia[J]. Jci Insight, 2017, 2(6):e92002.
[9] Latour C, Wlodarczyk MF, Jung G, et al. Erythroferrone contributes to hepcidin repression in a mouse model of malarial anemia[J]. Haematologica, 2017, 102(1):60~68.
[10] 中华人民共和国卫生部.慢性阻塞性肺疾病诊断标准[J].国际呼吸杂志,2011,31(1):1~2.
[11] Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of iron disorders[J]. Blood, 2016, 127(23):2809~2813.
[12] Wang CY, Babitt JL. Hepcidin regulation in the anemia of inflammation[J]. Current Opinion in Hematology, 2016, 23(3):189~197.
[13] Xiang L, Rhee DK, Malhotra R, et al. Progesterone receptor membrane component-1 regulates hepcidin biosynthesis[J]. Journal of Clinical Investigation, 2016, 126(1):389~401. |
|
|
|
2019, Vol. 25 
